Neumora Therapeutics, Inc. (NMRA) stock
NMRANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$0.33−0.03 (-9.47%)
Close on Nov 17, 2026Market cap $62.85MP/E –Yield –
Neumora Therapeutics shares outstanding
Diluted shares outstanding: the weighted share count used for earnings per share, adjusted for stock splits.
Neumora Therapeutics's shares outstanding was 185M at Jun 30, 2026. For fiscal 2025 it was 163M, up 2.5% from the year before.
Annual shares outstanding
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 163M | +2.5% |
| FY2024 | Dec 31, 2024 | 159M | +145.1% |
| FY2023 | Dec 31, 2023 | 65M | +139.0% |
| FY2022 | Dec 31, 2022 | 27M | – |
Quarterly shares outstanding
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | 185M | +14.5% |
| Q1 FY2026 | Mar 31, 2026 | 180M | +11.4% |
| Q4 FY2025 | Dec 31, 2025 | 169M | +4.7% |
| Q3 FY2025 | Sep 30, 2025 | 162M | +1.4% |
| Q2 FY2025 | Jun 30, 2025 | 162M | +1.7% |
| Q1 FY2025 | Mar 31, 2025 | 161M | +2.2% |
| Q4 FY2024 | Dec 31, 2024 | 161M | +244.8% |
| Q3 FY2024 | Sep 30, 2024 | 160M | +429.7% |
| Q2 FY2024 | Jun 30, 2024 | 159M | +443.0% |
| Q1 FY2024 | Mar 31, 2024 | 158M | +458.0% |
| Q3 FY2023 | Sep 30, 2023 | 47M | +68.9% |
| Q2 FY2023 | Jun 30, 2023 | 30M | – |
| Q1 FY2023 | Mar 31, 2023 | 29M | – |
| Q4 FY2022 | Dec 31, 2022 | 28M | – |
| Q3 FY2022 | Sep 30, 2022 | 28M | – |
See a number that looks wrong?